Molecular tumor markers for asbestos-related mesothelioma: Serum diagnostic markers

October 17, 2006 | Comments Off on Molecular tumor markers for asbestos-related mesothelioma: Serum diagnostic markers

Pathology International. 2006 Nov;56(11):649-54. [Link] Maeda M, Hino O. Immuno-Biological Laboratories, Fujioka, Gunma, Japan. Abstract Mesothelioma is an aggressive tumor arising from the mesothelium, and is usually associated with previous…

The effect of a novel transition state inhibitor of methylthioadenosine phosphorylase on pemetrexed activity

October 17, 2006 | Comments Off on The effect of a novel transition state inhibitor of methylthioadenosine phosphorylase on pemetrexed activity

Molecular Cancer Therapy. 2006 Oct;5(10):2549-55. [Link] Chattopadhyay S, Zhao R, Tsai E, Schramm VL, Goldman ID. Department of Medicine and Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, New York…

Silencing the receptor EphA2 suppresses the growth and haptotaxis of malignant mesothelioma cells

October 17, 2006 | Comments Off on Silencing the receptor EphA2 suppresses the growth and haptotaxis of malignant mesothelioma cells

Cancer. 2006 Oct 13; [Epub ahead of print] [Link] Najmunnisa Nasreen, PhD, Kamal A. Mohammed, PhD, Veena B. Antony, MD * Division of Pulmonary and Critical Care Medicine, Department of…

Unique Uptake of Acid-Prepared Mesoporous Spheres by Lung Epithelial and Mesothelioma Cells

October 14, 2006 | Comments Off on Unique Uptake of Acid-Prepared Mesoporous Spheres by Lung Epithelial and Mesothelioma Cells

American Journal of Respiratory Cell and Molecular Biology. 2006 Oct 12; [Epub ahead of print] [Link] Steven R Blumen1, Kai Cheng2, Maria E Ramos-Nino1, Douglas J Taatjes1, Daniel J Weiss3,…

Epidemiology of peritoneal mesothelioma: a review

October 13, 2006 | Comments Off on Epidemiology of peritoneal mesothelioma: a review

Annals of Oncology. 2006 Oct 9; [Epub ahead of print] [Link] P. Boffetta 1 * 1 International Agency for Research on Cancer, Lyon, France * To whom correspondence should be…

Morbidity and Mortality Assessment of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Diffuse Malignant Peritoneal Mesothelioma—A Prospective Study of 70 Consecutive Cases

October 13, 2006 | Comments Off on Morbidity and Mortality Assessment of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Diffuse Malignant Peritoneal Mesothelioma—A Prospective Study of 70 Consecutive Cases

Annals of Surgical Oncology. 2006 Oct 10; [Epub ahead of print] [Link] Yan TD, Edwards G, Alderman R, Marquardt CE, Sugarbaker PH. Peritoneal Surface Malignancy Program, Washington Cancer Institute, Washington…

5-year prospective results of trimodality treatment for malignant pleural mesothelioma

October 13, 2006 | Comments Off on 5-year prospective results of trimodality treatment for malignant pleural mesothelioma

The Journal of Cardiovascular Surgery (Torino). 2006 Oct;47(5):595-601. [Link] Pagan V, Ceron L, Paccagnella A, Pizzi G. Division of Thoracic Surgery, Umberto I General Hospital, Venezia-Mestre, Italy. Abstract Aim: Even…

Aurora kinase inhibitors: a new class of targeted drugs in cancer

October 10, 2006 | Comments Off on Aurora kinase inhibitors: a new class of targeted drugs in cancer

Clinical Lung Cancer. 2006 Sep;8(2):93-8. [Link] Gautschi O, Mack PC, Davies AM, Lara PN Jr, Gandara DR. University of California Davis Cancer Center, Sacramento, CA; E-mail: oliver.gautschi@ucdmc.ucdavis.edu. Abstract Aurora kinases…

Sarcomatous pleural mesothelioma metastatic to left ventricular endocardium

October 7, 2006 | Comments Off on Sarcomatous pleural mesothelioma metastatic to left ventricular endocardium

Angiology. 2006 Aug-Sep;57(4):517-21. [Link] Senkottaiyan N, Seacord LM, Fulling KH, Birchem JA, Fraley MA, Alpert MA. Department of Medicine and Pathology, St. John’s Mercy Medical Center, St. Louis, MO 63141,…

Drug targets to pro-angiogenetic factors with special reference to primary peritoneal mesothelioma

October 5, 2006 | Comments Off on Drug targets to pro-angiogenetic factors with special reference to primary peritoneal mesothelioma

Endocrine, Metabolic & Immune Disorders Drug Targets. 2006 Sep;6(3):271-7. [Link] Ranieri G, Ruggieri E, Falco G, Zizzo N, Mattioli E, Zito AF, Patruno R, Gasparini G. Department of Experimental Oncology,…

Categories